| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Janux Therapeutics, Inc. (JANX) has 13 insiders with recent SEC Form 4 filings, including 1 buy and 0 sells. JANX is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 264.7K | $4.26M | - | |
| Other | 155.8K | $2.51M | - | |
| Other | 101.5K | $1.63M | - | |
| Other | 100.1K | $1.61M | - | |
| Other | 83.1K | $1.34M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 15, 2021 | Reardon Tighe71 | Acting Chief Financial Officer | Buy | 629,411 | $17.00 | $10,699,987.00 | +16.3% | +52.6% | -37.6% |